スタチンは,内皮原幹細胞のテロメア再結合因子TRF2のアップレギュレーションにより,移動能力を高めます
Ioakim Spyridopoulos1, Judith Haendeler, Carmen Urbich
1Molecular Cardiology, Department of Internal Medicine IV, University of Frankfurt, Frankfurt, Germany.
Circulation
|November 3, 2004
まとめ
スタチンは,テロメアキャピングタンパク質TRF2を強化し,細胞機能を保ち,エンドセリアル原始細胞の衰老を防止します. この研究は,ステチン薬がテロメア生物学と細胞治療の可能性に与える新たな有益な効果を明らかにしています.
科学分野:
- 細胞生物学 細胞生物学
- 分子生物学は分子生物学である.
- 遺伝学 遺伝学とは
背景:
- 内皮原生細胞 (EPC) は,ex vivo培養中に複製性老化を経験し,細胞療法での使用を制限しています.
- 衰老はテロメア機能不全と関連しており,ミトースクロックと文化ストレスの影響を受けます.
- ステチン媒介によるEPCの機能増強におけるテロメア生物学の役割は,明らかにする必要があります.
研究 の 目的:
- ステチン誘発による内皮原生細胞 (EPC) の機能強化におけるテロメア生物学の役割を調査する.
- スタチンが,培養されたEPCの早期老化を緩和できるかどうかを判断する.
- スタチンがテロメア機能とEPCに影響するメカニズムを探求する.
主な方法:
- 人間のEPCを分離し,培養した.
- テロメアの長さは,光インシトゥハイブリデーション (Flow-FISH) を使用して測定されました.
- TRF2 (テロメア再結合因子) とChk2 (チェックポイントキナーゼ2) の発現は,免疫ボルトリングとqRT-PCRで評価されました.
主要な成果:
- エクスビヴォで培養されたEPCはテロメアの侵食を示さなかった.
- スタチンの治療 (アトリバスタチン,メバスタチン) は,mRNAを変更することなくTRF2タンパク質のレベルを上昇させ,転写後の調節を示唆しました.
- スタチンは,テロメア機能障害のマーカーであるChk2誘導を抑制し,この効果はTRF2.2に依存していました.
結論:
- エクスビボEPC培養は,TRF2の損失によるテロメア"解封"につながります.
- スタチンは,TRF2-依存のトランスクリプション後のメカニズムを通じて,EPCの機能的低下を防ぐ.
- この研究は,ステチン薬がテロメア生物学に与える新たな有益な影響を実証しています.
さらに関連する動画
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
関連する概念動画
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:24Cellular Membranes and Drug Transport
Drugs must traverse multiple biological barriers, such as multi-layered skin, single-layered intestinal epithelium, and the plasma membrane, to reach their target sites within the body. The plasma membrane, a highly structured composite of phospholipids, carbohydrates, and proteins, is the cell's protective boundary, facilitating selective substance exchange.
Phospholipids arrange themselves into a bilayer, with hydrophilic heads oriented outward and hydrophobic tails facing inward.
Phospholipids arrange themselves into a bilayer, with hydrophilic heads oriented outward and hydrophobic tails facing inward.
01:06Carrier-Mediated Transport
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...